Swedish Orphan buys Dova for $915mm
Swedish Orphan Biovitrum AB (Sobi) signed a definitive agreement to acquire Dova Pharmaceuticals Inc., a public three-year-old hematology drug company. The total potential value of the deal could hit $915mm, including $27.50 per Dova share in cash (a 55% premium to the 10-day pre-announcement market average) and contingent value rights entitling Dova shareholders to $1.50 per share.
- Specialty Pharmaceuticals
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com